Stopping poliovirus vaccination after eradication: Issues and challenges

Bulletin of the World Health Organization

Volumn 78, Issue 3, 2000, Pages 347-357

  Wood, D J ^a   Sutter, R W ^b   Dowdle, W R ^c  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Task Force Child Survival and Devmt   (United States)

Author keywords

Certification, standards; Immunization, trends; Poliomyelitis, prevention and control; Polioviruses, human 1 3, pathogenicity

Indexed keywords

INACTIVATED VIRUS VACCINE; LIVE VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

DISEASE CONTROL; HEALTH CARE; POLIOMYELITIS; VACCINATION;

ADOLESCENT; ADULT; BIOLOGICAL WARFARE; CERTIFICATION; CHILD; CONFERENCE PAPER; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; PATHOGENICITY; PERSISTENT VIRUS INFECTION; POLIOMYELITIS; POLIOMYELITIS VIRUS; STANDARD; VACCINATION; VIRUS EXCRETION; VIRUS TRANSMISSION;

CRITIQUE; DELIVERY OF HEALTH CARE; DISEASES; HEALTH; HEALTH SERVICES; IMMUNIZATION; INTERNATIONAL AGENCIES; ORGANIZATIONS; POLIOMYELITIS--PREVENTION AND CONTROL; PRIMARY HEALTH CARE; UN; VACCINATION; VIRAL DISEASES; WHO; WORLD;

BIOLOGICAL WARFARE; HEALTH POLICY; HIV INFECTIONS; HUMANS; IMMUNIZATION PROGRAMS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; WORLD HEALTH ORGANIZATION;

EID: 0034070798     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (62)

1. World Health Assembly. Global eradication of poliomyelitis by the year 2000. Geneva, World Health Organization, 1988 (Resolution WHA41.28).
2. Progress towards global poliomyelitis eradication, as of May 1999. Weekly Epidemiological Record, 1999, 74 (21): 165-170.
3. Expanded Programme on Immunization. Certification of poliomyelitis elimination - the Americas, 1994. Weekly Epidemiological Record, 1994, 69 (40): 293-295.
4. Final stages of poliomyelitis eradication, WHO Western Pacific Region, 1997-1998. Weekly Epidemiological Record, 1999, 74 (3): 20-24.
5. Sutter RW, Cochi SL, Melnick JL. Live attenuated poliovirus vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines, 3rd ed. Philadelphia, W.B. Saunders Company, 1999: 364-408.
6. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: Introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, 1997, 46 (RR3): 1-25.
7. Global Programme for Vaccines and Immunization. Report of the First Meeting of the Global Commission for the Certification of the Eradication of Poliomyelitis. Geneva, World Health Organization, 1995 (unpublished WHO document WHO/EPI/GEN/95.6).
8. Global Programme for Vaccines and Immunization. Proposed global action plan and timetable for safe handling and maximum laboratory containment of wild polioviruses and potentially infectious materials, versions for public comment, June 1998. Geneva, World Health Organization, 1998 (unpublished WHO document WHO/EPI/GEN/98.05).
9. Global action plan for laboratory containment of wild polioviruses. Geneva, World Health Organization, 1999 (unpublished document WHO/V&B/99.32).
10. Maintenance and distribution of transgenic mice susceptible to human viruses: Memorandum from a WHO meeting. Bulletin of the World Health Organization, 1993, 71: 497-502.
11. Global eradication of poliomyelitis. Report of the meeting for stopping polio immunization, Geneva, 23-25 March 1998. Geneva, World Health Organization, 1998 (unpublished document WHO/EPI/GEN/98.12).
12. Fine P, Carneiro IAM. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. American Journal of Epidemiology, 1999, 150: 1001-1021.
13. Fox JP, Hall CE. Experimental studies with vaccine strains of polioviruses. In: Viruses in families. Littleton, MA, PSG Publishing Company, Inc., 1980, 7: 152-195.
14. Mas Lago P. Eradication of poliomyelitis in Cuba. Bulletin of the World Health Organization, 1999, 77: 681-687.
15. Mas Lago P et al. [Circulation of poliovirus in the child population of Cuba]. Boletin Oficina Sanita Panamericana, 1975, 87: 443-449 (in Spanish).
16. Mas Lago P et al. Serological markers as indicator of no circulation of poliovirus in Cuba. Revista Cubana de medicina tropical, 1992, 44: 177-180.
17. Manor Y et al. Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian Authority. Journal of Clinical Microbiology, 1999, 37: 1670-1675.
18. Domok I et al. Enterovirus survey in children after mass vaccination with live attenuated polioviruses. British Medical Journal, 1962, 1: 743-746.
19. Domok I. Experience associated with the use of live poliovirus vaccine in Hungary, 1959-1982. Review of Infectious Diseases, 1984, 6 (Suppl. 2): S413-S418.
20. Strebel PM et al. Paralytic poliomyelitis in Romania, 1984-1992: Evidence for a high risk of vaccine-associated disease and reintroduction of wild-virus infection. American Journal of Epidemiology, 1994, 140: 1111-1124.
21. Kew OM et al. Molecular epidemiology of polioviruses. Seminars in Virology, 1995, 6: 401-414.
22. Patriarca PA, Sutter RW, Oostvogel PM. Outbreaks of paralytic poliomyelitis, 1976-1995. Journal of Infectious Diseases, 1997, 175 (Suppl.1): S165-S172.
23. Bijkerk H. Poliomyelitis in the Netherlands, 1978. Developments in Biological Standardization, 1979, 43: 195-206.
24. Oostvogel PM et al. Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-93. Lancet, 1994, 344: 665-670.
25. Furesz J, Armstrong RE, Contreras G. Viral and epidemiological links between poliomyelitis outbreaks in unprotected communities in Canada and the Netherlands. Lancet, 1978, 2: 1248.
26. Foote FM et al. Polio outbreak in a private school. Connecticut Medicine, 1993, 37: 643-644.
27. Schonberger LR et al. Control of paralytic poliomyelitis in the United States. Reviews of Infectious Diseases, 1984, 6 (Suppl. 2): S424-S426.
28. Imam H, Ismail HJM, Lal M. Poliomyelitis in Malaysia: two confirmed cases after six years without polio. Annals of Tropical Paediatrics, 1993, 13: 339-343.
29. Schaap GJP et al. The spread of wild poliovirus in the well-vaccinated Netherlands in connection with the 1978 epidemic. Progress in Medical Virology, 1984, 29: 124-140.
30. Centers for Disease Control and Prevention. Lack of evidence for wild poliovirus circulation - United States, 1993. Morbidity and Mortality Weekly Report, 1995, 43: 957-959.
31. Centers for Disease Control and Prevention. Isolation of wild poliovirus type 3 among members of a religious community, Alberta, Canada, 1993. Morbidity and Mortality Weekly Report, 1993, 42: 337-339.
32. Department of Health. Preliminary report of wild poliovirus isolation in Alberta, 1993. Canada Communicable Disease Report, 1993, 19-8: 57-58.
33. Sutter RW et al. A large outbreak of poliomyelitis following cessation of vaccination in Samarkand, 1993-1994. Journal of Infectious Diseases, 1997, 175 (Suppl. 1): S82-S85.
34. Oblapenko G, Sutter RW. Status of poliomyelitis eradication in Europe and the Central Asian Republics of the former Soviet Union. Journal of Infectious Diseases, 1997, 175 (Suppl. 1): S76-S81.
35. Prevots DR et al. Outbreak of poliomyelitis in Albania, 1996: high attack rate among adults and apparent interruption of transmission following a nationwide campaign with oral poliovirus vaccine. Clinical Infectious Diseases, 1998, 26: 419-425.
36. MacCallum FO. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. London, Medical Research Council, Medical Research Council Special Report Series, 310, 1971: 72-85
37. Hara M et al. Antigenic analysis of polioviruses isolated from a child with gammaglobulinemia. Microbiology and Immunology, 1981, 25: 905-913.
38. WHO Scientific Group. Primary immunodeficiency diseases. Clinical and Experimental Immunology, 1997, 109 (Suppl. 1): 1-28.
39. Rosen FS, Cooper MD, Wedgwood RJP. The primary immunodeficiencies. New England Journal of Medicine, 1995, 333: 431-440.
40. Grumach AS et al. Brazilian report on primary immunodeficiencies in children: 166 cases studied over a follow-up time of 15 years. Journal of Clinical Immunology, 1997, 17: 340-345.
41. Pleconaril, Win-63843. Drugs of the Future, 1997, 22: 40-44.
42. Romero JR et al. Pleconaril treatment of vaccine-acquired poliovirus. In: Abstracts of Pediatric Academy Societies' 1999 Annual Meeting, 1-4 May 1999, San Francisco, CA, USA (Abstract No. 1012). Washington, DC, American Society for Microbiology.
43. Wyatt HV. Poliomyelitis in hypogammaglobulinemics. Journal of Infectious Diseases, 1973, 151: 802-806.
44. Sutter RW, Prevots DR. Vaccine-associated paralytic poliomyelitis among immunologically abnormal persons. Infections in Medicine, 1994, 11: 426, 429-430, 435-438.
45. Misbah SA et al. Prolonged faecal excretion of poliovirus in a nurse with common variable hypogammaglobulinaemia. Postgraduate Medical Journal, 1991, 67: 301-303.
46. Centers for Disease Control and Prevention. Prolonged poliovirus excretion in an immunodeficient person with vaccine-associated paralytic poliomyelitis. Morbidity and Mortality Weekly Report, 1997, 46: 641-643.
47. Kew OM et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. Journal of Clinical Microbiology, 1998, 36: 2893-2899.
48. Bellmunt A et al. Evolution of poliovirus type 1 during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology, 1999, 265: 178-184.
49. Savilahti E et al. Inadequacy of mucosal IgM antibodies in selective IgA deficiency: excretion of attenuated polio viruses is prolonged. Journal of Clinical Immunology, 1988, 8: 89-94.
50. Vernon A et al. Paralytic poliomyelitis and HIV infection in Kinshasa, Zaire. In: Sixth International Conference on AIDS, 20-24 June 1990, San Francisco, CA, USA.
51. Ion-Neldescu N et al. Vaccine-associated paralytic poliomyelitis and HIV infection. Lancet, 1994, 343: 51-52.
52. Chitsike I, van Furth R. Paralytic poliomyelitis associated with live oral poliomyelitis vaccine in a child with HIV infection in Zimbabwe: case report. British Medical Journal, 1999, 318: 841-843.
53. Wimmer E. Do recombinants with other enteroviruses pose a threat? Paper presented at: Meeting on the Scientific Basis for Stopping Immunization, WHO Global Programme for Vaccines and Immunization, Geneva, 1998. Geneva, World Health Organization, 1998 (unpublished document WHO/EPI/GEN/ 98.12).
54. Gromeier M et al. Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence. Journal of Virology, 1999, 73: 958-964.
55. Dowdle WR, Birmingham ME. The biologic principles of poliovirus eradication. Journal of Infectious Diseases, 1997, 175 (Suppl. 1): S286-S292.
56. Mulders MN et al. Genetic analysis of wild-type poliovirus importation into the Netherlands (1979-1995). Journal of Infectious Diseases, 1997, 176: 617-624.
57. Dove AW, Racaniello VR. The polio eradication effort: Should vaccine eradication be next? Science, 1997, 277: 779-780.
58. Hull HF, Aylward RB. Ending polio immunization. Science, 1997, 277: 780.
59. Sabin AB. Paralytic consequences of poliomyelitis infection in different parts of the world and in different population groups. American Journal of Public Health, 1951, 41: 1215-1230.
60. Horstmann DM. Poliomyelitis: severity and type of disease in different age groups. Annals of the New York Academy of Sciences, 1955, 61: 956-967.
61. Molla A, Paul AV, Wimmer E. Cell-free, de novo synthesis of poliovirus. Science, 1991, 254: 1647-1651.
62. Martin J et al. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637 day period of virus excretion. Journal of Virology, in press.